our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SZ003

News alerts, weekly reports and conference planners

Company:

Guangdong ProCapZoom Biosci

Drug class:

NK cell stimulant

Related drugs:

‹

cytotoxic lymphocyte-based cancer vaccine (0)

GCC4001 (0)

CAR-ITNK cells (0)

CAR-NK-CD19 cells (0)

CAR.70/IL15-transduced CB-NK cells (0)

CAR19-CYNK (0)

CB CAR-NK019 (0)

CBT101 (0)

CD123 targeted CAR-NK (0)

CD33/CLL1 dual CAR-NK cell (0)

CDH17 CAR-NK cell therapy (0)

CHM 2301 (0)

CIML NK (0)

CLDN6-CAR-NK cell therapy (0)

DC vaccine for prostate cancer (0)

primed NK cell therapy (0)

NK/γδ T cell-enriched cell therapy (0)

NK92-CD16-158V (0)

NKG2D CAR-NK cell therapy (0)

NKG2D-CAR-NK92 cells (0)

Super NK cell therapy (0)

TROP2-CAR-NK (0)

UD TGFbetai NK cells (0)

›

4ms

Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)

P=N/A, N=12, Recruiting, Shantou University Medical College | Not yet recruiting --> Recruiting

4 months ago

Enrollment open • Metastases

GPC3 (Glypican 3)

SZ003

over1year

Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)

P=N/A, N=12, Not yet recruiting, Shantou University Medical College

over 1 year ago

New trial

GPC3 (Glypican 3)

SZ003